272 related articles for article (PubMed ID: 15385126)
1. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
2. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
Landoni F; Pellegrino A; Cormio G; Milani R; Maggioni A; Mangioni C
Acta Obstet Gynecol Scand; 1998 Feb; 77(2):233-7. PubMed ID: 9512334
[TBL] [Abstract][Full Text] [Related]
3. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
4. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
7. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
8. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
9. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
10. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.
Satthapong D; Tangjitgamol S; Manusirivithaya S; Pataradool K
J Med Assoc Thai; 2007 Mar; 90(3):411-9. PubMed ID: 17427513
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of clear cell carcinoma of the ovary.
Behbakht K; Randall TC; Benjamin I; Morgan MA; King S; Rubin SC
Gynecol Oncol; 1998 Aug; 70(2):255-8. PubMed ID: 9740700
[TBL] [Abstract][Full Text] [Related]
15. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
16. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
17. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
18. Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum.
Firat S; Erickson B
Gynecol Oncol; 2001 Feb; 80(2):213-20. PubMed ID: 11161862
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.
Muntz HG; Malpass TW; McGonigle KF; Robertson MD; Weiden PL
Cancer; 2008 Aug; 113(3):490-6. PubMed ID: 18521923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
